| Literature DB >> 32430485 |
Jinge Zhao1, Shu Ning1, Wei Lou1, Joy C Yang1, Cameron M Armstrong1, Alan P Lombard1, Leandro S D'Abronzo1, Christopher P Evans1,2, Allen C Gao3,2,4, Chengfei Liu3,2.
Abstract
The next-generation antiandrogen drugs, XTANDI (enzalutamide), ZYTIGA (abiraterone acetate), ERLEADA (apalutamide) and NUBEQA (darolutamide) extend survival times and improve quality of life in patients with advanced prostate cancer. Despite these advances, resistance occurs frequently and there is currently no definitive cure for castration-resistant prostate cancer. Our previous studies identified that similar mechanisms of resistance to enzalutamide or abiraterone occur following treatment and cross-resistance exists between these therapies in advanced prostate cancer. Here, we show that enzalutamide- and abiraterone-resistant prostate cancer cells are further cross-resistant to apalutamide and darolutamide. Mechanistically, we have determined that the AKR1C3/AR-V7 axis confers this cross-resistance. Knockdown of AR-V7 in enzalutamide-resistant cells resensitize cells to apalutamide and darolutamide treatment. Furthermore, targeting AKR1C3 resensitizes resistant cells to apalutamide and darolutamide treatment through AR-V7 inhibition. Chronic apalutamide treatment in C4-2B cells activates the steroid hormone biosynthesis pathway and increases AKR1C3 expression, which confers resistance to enzalutamide, abiraterone, and darolutamide. In conclusion, our results suggest that apalutamide and darolutamide share similar resistant mechanisms with enzalutamide and abiraterone. The AKR1C3/AR-V7 complex confers cross-resistance to second-generation androgen receptor-targeted therapies in advanced prostate cancer. ©2020 American Association for Cancer Research.Entities:
Mesh：
Substances：
Year: 2020 PMID： 32430485 PMCID： PMC8855880 DOI： 10.1158/1535-7163.MCT-20-0015
Source DB: PubMed Journal: Mol Cancer Ther ISSN： 1535-7163 Impact factor: 6.261